Frank I. Navetta - Concepedia

Concepedia

Author

Frank I. Navetta

Duke Medical Center

Also Known As

F Navetta, FRANK I. NAVETTA, Frank I Navetta, Frank I. Navetta, Frank Navetta, Navetta, Frank I.

19

Publications

1.6K

Citations

12

H-Index

29

Concepts

All Affiliations

Duke Medical Center Cleveland Clinic Duke University Francis Hospital University of Maryland, Baltimore

FI

About

Frank I. Navetta is an author at Duke Medical Center specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	345
2	Public Health	3	3	198
3	Emergency Medicine	3	3	155
4	Pharmacology	2	2	77
5	Health Sciences	1	1	17

Frank I. Navetta

×

12

Publications

1.6K

Citations

12

H-Index

	Year	Citations
Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction E. Magnus Ohman, Neal S. Kleiman, Gerald M. Gacioch, Circulation	1997	380
Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention Steven R. Steinhubl, J. David Talley, Gregory A. Braden, Circulation	2001	358
Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention James E. Tcheng, Robert A. Harrington, Kandice Kottke‐Marchant, Circulation	1995	280
Effects of Integrelin, a Platelet Glycoprotein IIb/IIIa Receptor Antagonist, in Unstable Angina Steven P. Schulman, Pascal J. Goldschmidt‐Clermont, Eric J. Topol, Circulation	1996	108
Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery James D. Boehrer, Dean J. Kereiakes, Frank I. Navetta, The American Journal of Cardiology ThrombopoiesisThrombosisPercutaneous Coronary InterventionCoronary Bypass SurgeryProfound Platelet Inhibition	1994	100
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplasty Stephen G. Ellis, James E. Tcheng, Frank I. Navetta, Coronary Artery Disease	1993	71
A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: The Duke University clinical cardiology study (DUCCS) 1 Christopher M. O’Connor, Roderick B. Meese, Robert J. Carney, Journal of the American College of Cardiology ThrombosisIntravenous HeparinCardiovascular DiseaseMyocardial InfarctionRandomized Trial	1994	71
Predicting the risk of abrupt vessel closure after angioplasty in an individual patient Alan N. Tenaglia, Donald F. Fortin, Robert M. Califf, Journal of the American College of Cardiology Heart FailureIndividual PatientEndovascular TechniqueCardiovascular DiseasePatient Safety	1994	67
Effects of atrial natriuretic peptide on the coronary arterial vasculature in humans. Alan Chu, K G Morris, W D Kuehl, Circulation HypertensionCardiovascular PharmacologyCoronary FlowCardiovascular FunctionCoronary Artery Disease	1989	60
Percutaneous transluminal coronary angioplasty in octogenarians as an effective therapy for angina pectoris John D. Jackman, Frank I. Navetta, Jack E. Smith, The American Journal of Cardiology Percutaneous Coronary InterventionCardiovascular DiseaseVascular SurgeryAngina PectorisSurgery	1991	30

Page 1